09/96/376 COC

OPE 4AQ

N THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Letters Patent of:

Docket No.: PF524P1

Ruben et al.

Patent No.: 6,969,519

Issued: November 29, 2005

For: Methods of Using an Agonistic Human Tumor

Necrosis Factor Receptor (TR17) Antibody (as

amended)

REQUEST FOR CERTIFICATE OF CORRECTION PURSUANT TO 37 CFR 1.322

Attention: Certificate of Correction Branch Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 Of Correction

Sir:

Upon reviewing the above-identified patent, Patentee noted typographical errors which should be corrected. Applicants respectfully request publication of a Certificate of Correction as follows:

In the Title:

The word "antibody" should be at the end of the Title. Please replace the Title with

--Methods of Using An Agonistic Human Tumor Necrosis Factor Receptor (TR17) Antibody--.

On the Title Page:

Under "Other Publications," under INID code (56), at the Marriette et al. reference, please replace "zTNF4" with --zTNF4--.

In the Claims:

Claim 2, at column 229, please replace "inonoclonal" with --monoclonal--.

Claim 5, column 229, please replace "claim wherein" with --claim 1 wherein--.

Support for the correction of the Title can be found in the Examiner's amendment to the Title in the Notice of Allowability mailed May 6, 2005.

Support for the correction of the Marriette et al. reference can be found in the presentation of that reference on the Form PTO/SB08 submitted by Applicants with the Information Disclosure Statement filed October 29, 2003 (cited thereon as reference AL).

Support for correction to claims 2 and 5 can be found in the presentation of claims 68 and 71, respectively, in Applicants amendment filed April 1, 2005. Claims 68 and 71 depended from claim 36, each of which was renumbered as claims 2, 5, and 1, respectively.

The above errors were not in the application as filed or amended by Patentees, and thus appear to be the fault of the Patent and Trademark Office. Accordingly, it is hereby requested that a Certificate of Correction Under 37 C.F.R. § 1.322 be issued for the above-identified patent. Pursuant to 35 U.S.C. § 254 and 37 C.F.R. § 1.322, no fee is required.

Submitted herewith is a proposed Certificate of Correction. Patentees respectfully request the issuance of the Certificate of Correction. effecting such amendment. Patentee respectfully solicits the granting of the requested Certificate of Correction.

Dated: June 22, 2006

Respectfully submitted,

Michele Shannon

Registration No.: 47,075

HUMAN GENOME SCIENCES, INC.

Intellectual Property Dept. 14200 Shady Grove Road Rockville, Maryland 20850

(301) 354-3930

KKH/MS/ba

JUN 27 ZUU6

Patent No.: 6,969,519 2 Docket No.: PF524P1

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

Page _1_ of _1_

PATENT NO.

6,969,519

APPLICATION NO.

09/961,376

ISSUE DATE

November 29, 2005

INVENTOR(S)

Ruben et al.

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In the Title:

Delete "Methods of Using an Agonistic Antibody Human Tumor Necrosis Factor Receptor (TR17)" and replace with --Methods of Using An Agonistic Human Tumor Necrosis Factor Receptor (TR17) Antibody--.

Title Page:

Under "Other Publications," INID (56), at the Marriette et al. reference, delete "zTNF4" and insert therefor --zTNF4--.

In the Claims:

Claim 2, at column 229, delete "inonoclonal" and insert therefor --monoclonal--.

Claim 5, at column 229, delete "claim wherein" and insert therefor --claim 1 wherein--.